About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Innovation Engine New Era Microbiome Therapeutics Discuva Platform Scientific Literature & Publications Investors & Media Investor Center Media Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Summit Presentations Careers
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial
Ridinilazole for Clostridium difficile Infection: Human Gut Microbiome Profiles from a Phase 2 Clinical Trial October 3, 2018 By Mary Alvarado
